Your browser doesn't support javascript.
loading
Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.
Ternette, Nicola; Block, Peter D; Sánchez-Bernabéu, Álvaro; Borthwick, Nicola; Pappalardo, Elisa; Abdul-Jawad, Sultan; Ondondo, Beatrice; Charles, Philip D; Dorrell, Lucy; Kessler, Benedikt M; Hanke, Tomás.
Afiliación
  • Ternette N; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom nicola.ternette@ndm.ox.ac.uk.
  • Block PD; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Sánchez-Bernabéu Á; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Universitat de Barcelona, Barcelona, Spain.
  • Borthwick N; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Pappalardo E; Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
  • Abdul-Jawad S; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Ondondo B; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Charles PD; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Dorrell L; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Kessler BM; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Hanke T; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
J Virol ; 89(11): 5760-71, 2015 Jun.
Article en En | MEDLINE | ID: mdl-25810538
UNLABELLED: Cytotoxic T cells substantially contribute to the control of intracellular pathogens such as human immunodeficiency virus type 1 (HIV-1). Here, we evaluated the immunopeptidome of Jurkat cells infected with the vaccine candidate MVA.HIVconsv, which delivers HIV-1 conserved antigenic regions by using modified vaccinia virus Ankara (MVA). We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify 6,358 unique peptides associated with the class I human leukocyte antigen (HLA), of which 98 peptides were derived from the MVA vector and 7 were derived from the HIVconsv immunogen. Human vaccine recipients responded to the peptide sequences identified by LC-MS/MS. Peptides derived from the conserved HIV-1 regions were readily detected as early as 1.5 h after MVA.HIVconsv infection. Four of the seven conserved peptides were monitored between 0 and 3.5 h of infection by using quantitative mass spectrometry (Q-MS), and their abundance in HLA class I associations reflected levels of the whole HIVconsv protein in the cell. While immunopeptides delivered by the incoming MVA vector proteins could be detected, all early HIVconsv-derived immunopeptides were likely synthesized de novo. MVA.HIVconsv infection generally altered the composition of HLA class I-associated human (self) peptides, but these changes corresponded only partially to changes in the whole cell host protein abundance. IMPORTANCE: The vast changes in cellular antigen presentation after infection of cells with a vectored vaccine, as shown here for MVA.HIVconsv, highlight the complexity of factors that need to be considered for efficient antigen delivery and presentation. Identification and quantitation of HLA class I-associated peptides by Q-MS will not only find broad application in T-cell epitope discovery but also inform vaccine design and allow evaluation of efficient epitope presentation using different delivery strategies.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Linfocitos T Citotóxicos / Antígenos de Histocompatibilidad Clase I / VIH-1 / Vacunas contra el SIDA / Antígenos Virales Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Virol Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Linfocitos T Citotóxicos / Antígenos de Histocompatibilidad Clase I / VIH-1 / Vacunas contra el SIDA / Antígenos Virales Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Virol Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido